July 20, 2010
Saladax Biomedical Achieves ISO Certification for Design, Manufacture and Distribution of In Vitro Diagnostics (Read More)
June 21, 2010
Saladax Biomedical Signs Deal with Bristol-Myers Squibb to Develop Clinical Diagnostics (Read More)
April 19, 2010
Saladax Biomedical Expands Executive Team with New Vice President of Clinical Development and Regulatory Affairs -- Gary Lee Feiss Joins Saladax to Lead Clinical Development for
MYCARE™ Portfolio of Personalized Medicine Assays (Read More)
April 6, 2010
Saladax Biomedical Executes Exclusive Distribution Agreement with FALCO SD for the 5-FU MYCARE Assay in Japan --Test May Prevent Reduced Efficacy or Excess Side Effects Through
Accurate Dosing of 5-Fluorouracil (Read More)
March 3, 2010
Saladax Biomedical Closes $8 Million Series C Financing. Accelerates Development of Personalized Patient Dosing For Cancer and CNS Disorders (Read More)
June 30, 2009
Saladax Biomedical, Inc. Signs Agreement With Stockholm's Karolinska University Hospital (Read More)
May 27, 2009
Saladax Biomedical Announces Distribution Agreement With Lab21 For Personalized Chemotherapy Management (PCM®) Kits (Read More)
May 12, 2009
Saladax Biomedical Receives Product Innovation Award. Personalized Chemotherapy Management® Tests Are Filling an Unmet Need
(Read More)
April 30, 2009
License From Saladax Biomedical is Foundation of New Molecular Oncology Test Launched My Myriad Genetics
(Read More)
April 14, 2009
Saladax Biomedical Receives Innovation Award from Ben Franklin Technology Partners iExchange....
(Read More)
October 7, 2008
Myriad Genetics (Nasdaq: MYGN, www.myriad.com) Acquires Novel Therapeutic Drug Management Technology from Saladax Biomedical
(Read More)
August 5, 2008
Saladax Biomedical 5-FU PCM® Immunoassay for Chemotherapy Treatment Individualization Promises Multiple Benefits in Treatment of Colorectal Cancer
(Read More)
July 24, 2008
Saladax Biomedical Enters Agreement With Karolinska University Hospital In Sweden To Supply 5-Fu Personalized Chemotherapy Management Assay
(Read More)
June 23, 2008
New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM™) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
(Read More)
June 17, 2008
Saladax Biomedical’s 5-FU Personalized Chemotherapy Management (PCM™) Assay CE Marked for Distribution in the EU
(Read More)
May 2, 2008
Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
(Read More)
January 27, 2008
Novel 5-Fluorouracil Immunoassay Proves to Be An Effective Tool for Monitoring 5-FU Blood Concentrations
(Read More)
December 12, 2007
Delaware Crossing Investor Group Makes a $260,000 Investment in Saladax Biomedical, Inc.
(Read More)
December 10, 2007
New York State Health Department Approves Busulfan Testing by Memorial Sloan-Kettering Cancer Center
(Read More)
May 18, 2007
Saladax Biomedical Launches First Analyte Specific Reagent* (ASR) for Determination of Busulfan Blood Concentrations.
(Read More)
March 12, 2007
Saladax Biomedical to Present at Leading Life Science Conferences in 2007
(Read More)
January 15, 2007
Olympus, in Cooperation With Saladax Biomedical, Prepares to Offer Testing in Support of Personalized Chemotherapy
(Read More)
October 30, 2006
ARUP Laboratories and Saladax Biomedical Sign Agreement for Busulfan Analyte Specific Reagents
(Read More)
June 4, 2006
Novel Monoclonal Antibodies to Measure Levels of 5-Fluorouracil in Plasma
(Read More)
April 3, 2006
Monoclonal Antibodies to Help Oncologists Measure Chemotherapy Levels in Plasma
(Read More)